Evidence map›Paper›PMID 37742207›Full record

ArticlemAbs

Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity.

Christopher B Lietz, Ekaterina Deyanova, Younhee Cho, Jon Cordia, Sarah Franc, Sally Kabro, Steven Wang, David Mikolon, Douglas D Banks

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Christopher B LietzDepartment of Pharmaceutical Candidate Optimization - DMPK, Bristol Myers Squibb, San Diego, CA, USA.
Ekaterina DeyanovaDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, Lawrenceville, NJ, USA.
Younhee ChoDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
Jon CordiaDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
Sarah FrancDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
Sally KabroDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
Steven WangDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
David MikolonDepartment of Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Douglas D BanksDepartment of Pharmaceutical Candidate Optimization - DPAS, Bristol Myers Squibb, San Diego, CA, USA.
Bristol-Myers Squibb (United States) · USBristol-Myers Squibb (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite tyrosine sulfation being a relatively common post-translational modification (PTM) on the secreted proteins of higher eukaryotic organisms, there have been surprisingly few reports of this modification occurring in recombinant monoclonal antibodies (mAbs) expressed by mammalian cell lines and even less information regarding its potential impact on mAb efficacy and stability. This discrepancy is likely due to the extreme lability of this modification using many of the mass spectrometry methods typically used within the biopharmaceutical industry for PTM identification, as well as the possible misidentification as phosphorylation. Here, we identified sulfation on a single tyrosine residue located within the identical variable region sequence of a 2 + 1 bispecific mAbs heavy and heavy-heavy chains using a multi-enzymatic approach in combination with mass spectrometry analysis and examined its impact on binding, efficacy, and physical stability. Unlike previous reports, we found that tyrosine sulfation modestly decreased the mAb cell binding and T cell-mediated killing, primarily by increasing the rate of antigen disassociation as determined from surface plasmon resonance-binding experiments. We also found that, while this acidic modification had no significant impact on the mAb thermal stability, sulfation did modestly increase its rate of aggregation, presumably by lowering the mAb's colloidal stability as indicated by polyethylene glycol induced liquid-liquid phase separation experiments.

Indexed as

Antibodies, BispecificTyrosineAnimalsAntibodies, MonoclonalCell LineMammalsMass SpectrometryRecombinant ProteinsAntibodies, BispecificAntibodies, MonoclonalRecombinant ProteinsTyrosineBiotherapeuticmass spectrometrymonoclonal antibodypeptide mappost-translational modificationsulfotyrosine

Identifiers

PMID37742207
PMCPMC10519368
OpenAlexW4386995237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.